yttrium/סרטן

הקישור נשמר בלוח

בחר סוג מיון

עמוד 1 מ 389 תוצאות

KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE To evaluate Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status as a prognostic factor for survival after yttrium-90 ((90)Y) radioembolization for colorectal cancer (CRC) liver metastases. METHODS Consecutive patients with unresectable CRC liver metastases and documented KRAS

Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Current treatment of advanced-stage nasopharyngeal carcinoma (NPC) is not satisfactory. Here, we developed a folic acid (FA) modified, gefitinib (GEF) and yttrium 90 (Y90) co-loaded, core-shell structured lipid-polymer hybrid nanoparticles (FA-GEF-Y90-LPNP). The size and zeta potential, drug release

Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

A three-step avidin-biotin approach has been applied as a pretargeting system in radioimmunotherapy (RIT) as an alternative to conventional RIT with directly labelled monoclonal antibodies (MoAbs). Although dosimetric and toxicity studies following conventional RIT have been reported, these aspects

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Hepatocellular carcinoma (HCC) is the second most lethal malignancy globally and is increasing in incidence in the United States. Unfortunately, there are few effective systemic treatment options, particularly for disseminated disease. Glypican-3 (GPC3) is a proteoglycan cell surface receptor

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (90Y-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this therapy in patients with metastatic colon cancer.

Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90

Yttrium-90 microspheres: radiation therapy for unresectable liver cancer.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Hepatocellular carcinoma (HCC) constitutes a difficult health challenge because of its poor prognosis and limited treatment options. Most available therapies are used only for palliation. The use of yttrium-90 microspheres is a new intraarterial therapy consisting of beta-irradiating microspheres

Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE The aim of this study was to assess the effectiveness of yttrium-90 (90 Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET). METHODS From February 2006 to September 2015, 36 patients (19 male and 17 female, age 63.6 ± 9.4 years) who underwent 90 Y

Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC). Our objective was to report our early experience with this treatment modality from a nontransplant center. Treatment of patients with HCC was discussed

A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Over the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ( 90 Y) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However,

Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic

Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumors.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Selective internal radiation therapy with yttrium-90 microsphere radioembolization has been used to treat unresectable liver tumors and its acute toxicity has been well described. Subacute and long-term hepatic complications related to radioembolization however may be underreported in the

A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

BACKGROUND The management of unresectable, chemorefractory colorectal cancer liver metastases (CRCLM) is a clinical dilemma. Yttrium-90 (Y90) radioembolization is a potentially safe and effective treatment for patients with CRCLM who have failed conventional chemotherapy regimens. METHODS A

Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

OBJECTIVE Yttrium-90 (Y) radioembolization is increasingly used as a minimally invasive therapy for unresectable liver tumors; however, previous hepatectomy must be considered to avoid excessive hepatic insult. A retrospective analysis was undertaken to investigate the viability of performing

Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab.

רק משתמשים רשומים יכולים לתרגם מאמרים

התחבר הרשם

Yttrium-90 microspheres have been recently approved by the Food and Drug Administration and have become available to physicians in the United States for the treatment of hepatic neoplasia. Published results regarding the benefits of 90Y radioembolotherapy within the rapidly evolving landscape of

קודם
1
2
3
4
5
6
...
25
26
הַבָּא

הצטרפו לדף הפייסבוק שלנו

Herbal & Natural Medicine

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע

עובד ב 55 שפות
מרפא צמחי מרפא מגובה על ידי מדע
זיהוי עשבי תיבול על ידי דימוי
מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
קרא פרסומים מדעיים הקשורים לחיפוש שלך
חפש עשבי מרפא על פי השפעותיהם
ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים

הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם